News

Over abiraterone/prednisone alone, apalutamide plus abiraterone-prednisone proves survival benefit in patients with metastatic castration resistant prostate cancer.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

Bemcentinib is currently being studied in combination with pembrolizumab and has demonstrated a good safety profile.

Ocular adnexal region involvement remains rare, presenting in only between 1% to 5% of mantle cell lymphoma cases.

In an interview with Targeted Oncology, Rachna Shroff, MD, discusses the impact of ivosidenib’s approval on the cholangiocarcinoma space in greater detail.

DF1001 is currently being studied as both a monotherapy and a combination in a phase 1/2 study that is now recruiting across the United States.

American Oncology Network opens its third practice in Arizona with Desert Hematology Oncology.

The combination of lenvatinib and pembrolizumab is the current standard of care for ccRCC, however, most patients still experience disease progression. The addition of a third agent may lead to improvement in outcomes.

Compared with sunitinib, second-line treatment with ripretinib did not improve progression-free survival in patients with gastrointestinal stromal tumor.

The additional of nivolumab to chemotherapy improved event-free surivial in patients with resectable non-small cell lung cancer, meeting the primary end point of the CheckMate 816 trial.

The agent, EZM0414, will be explored in DLBCL, multiple myeloma, and non-multiple myeloma after the completion of a phase 1 dose-finding study.

After showing significant improvement in survival, a breakthrough therapy designation application for leronlimab has been submitted to the FDA.

TheADAGE study has shown that in both young and older patients, chemotherapy is manageable in the adjuvant setting.

Savolitinib in combination with durvalumab has been dosed to the first patient with MET-driven advanced papillary renal cell carcinoma in a phase 3 study.

Until the CONFIRM results, no phase 3 trial had demonstrated improvement survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy.

The phase 3 COMPOSE trial is the second trial to look at 177Lu-edotreotide in somatostatin receptor-positive disease.

Progression-free survival remained unaffected in patients with advanced biliary tract cancer after clinicians added either ramucirumab or merestinib to first-line chemotherapy.

Investigators set out to determine the relationship between prostate-specific antigen response and urinary and bowel adverse events, QOL deterioration, and prostate cancer-related invasive procedures.

Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.

The combination of dendritic cell-based immunotherapy in the second-line of treatment for patients with ovarian cancer proves beneficial.

The novel PARP inhibitor RP12146 has been administered to the first patient in a phase 1/1b clinical trial of patients with advanced solid tumors.

Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

Filip Janku, MD, PhD, discussed the efficacy of the PI3K inhibitor copanlisib in solid tumors in an interview with Targeted Oncology.

A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.

The PDUFA date for Cilta-Cel has been moved in order to evaluate new data and is now set for early 2022.

Here is a look back FDA happenings from October 2021.

Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.

he CINtec PLUS Cytology duel-stain biomarker technology was found to be more sensitive than Pap in detecting cervical precancer in women with HPV.

The biologics license application for toripalimab will undergo a speedy review by the FDA for consideration as a frontline treatment option for patients with advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin, and as a single-agent for the second-line or above treatment of recurrent or metastatic disease after platinum-containing chemotherapy.